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Early pathogenesis of Duchenne 
muscular dystrophy modelled in 
patient-derived human induced 
pluripotent stem cells
Emi Shoji1,2, Hidetoshi Sakurai1, Tokiko Nishino1, Tatsutoshi Nakahata1, Toshio Heike3, 
Tomonari Awaya3, Nobuharu Fujii5, Yasuko Manabe5, Masafumi Matsuo4 & Atsuko Sehara-
Fujisawa2
Duchenne muscular dystrophy (DMD) is a progressive and fatal muscle degenerating disease 
caused by a dystrophin deficiency. Effective suppression of the primary pathology observed in 
DMD is critical for treatment. Patient-derived human induced pluripotent stem cells (hiPSCs) are a 
promising tool for drug discovery. Here, we report an in vitro evaluation system for a DMD therapy 
using hiPSCs that recapitulate the primary pathology and can be used for DMD drug screening. 
Skeletal myotubes generated from hiPSCs are intact, which allows them to be used to model the 
initial pathology of DMD in vitro. Induced control and DMD myotubes were morphologically and 
physiologically comparable. However, electric stimulation of these myotubes for in vitro contraction 
caused pronounced calcium ion (Ca2+) influx only in DMD myocytes. Restoration of dystrophin by 
the exon-skipping technique suppressed this Ca2+ overflow and reduced the secretion of creatine 
kinase (CK) in DMD myotubes. These results suggest that the early pathogenesis of DMD can be 
effectively modelled in skeletal myotubes induced from patient-derived iPSCs, thereby enabling the 
development and evaluation of novel drugs.
Duchenne muscular dystrophy (DMD) is characterised by progressive muscle atrophy and weakness that 
eventually leads to ambulatory and respiratory deficiency from early childhood1. It is an X-linked reces-
sive inherited disease with a relatively high frequency of 1 in 3500 males1,2. DMD, which is responsible 
for DMD, encodes 79 exons and produces dystrophin, which is one of the largest known cytoskeletal 
structural proteins3. Most DMD patients have various types of deletions or mutations in DMD that create 
premature terminations, resulting in a loss of protein expression4. Several promising approaches could be 
used to treat this devastating disease, such as mutation-specific drug exon-skipping5,6, cell therapy7, and 
gene therapy1,2. Among these techniques, exon-skipping, which is a sequence-specific technique, has high 
efficacy and has potential for personalised medicine because of its specificity. However, it is still necessary 
to find drugs that are widely effective for many DMD patients despite the variability in their mutations.
The establishment of human induced pluripotent stem cells (hiPSCs)8 has led to a variety of new dis-
ease models9,10. Through their unlimited proliferation potential, patient-derived hiPSCs have advantages 
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over patient-derived somatic cells such as myoblasts or fibroblasts in drug screening. Myoblasts from 
patients are the most common cell sources for assessing the disease phenotypes of DMD11,12. However, 
the degree of skeletal muscle damage in patients varies depending on factors such as genetic background, 
age, and medical history. Previous reports have shown that muscle cell differentiation from DMD patient 
myoblasts is delayed and that these cells have poor proliferation capacity compared to those of healthy 
individuals11,12. Furthermore, repetitive regeneration of DMD muscle leads to reduction in the prolif-
eration potential of muscle satellite cells13,14. These phenotypes of DMD myoblasts are considered as 
secondary effects of chronic inflammation. In contrast, our study revealed that control and DMD myo-
blasts obtained by activating tetracycline-dependent MyoD transfected into iPS cells (iPStet-MyoD cells) 
have comparable growth and differentiation potential and can produce a large number of intact and 
homogeneous myotubes repeatedly. These properties permit the study of the early phenotypes of DMD 
that appear prior to inflammation.
The pathogenesis of DMD is initiated and progresses with muscle contraction. The degree of muscle 
cell damage at the early stage of DMD can be evaluated by measuring the leakage of creatine kinase (CK) 
into the extracellular space15. Several cell-damaging factors have been reported in DMD: accumulation 
of reactive oxygen species16, activation of nuclear factor kappa beta (NFκ B)17, and calpain activity18. 
However, excess calcium ion (Ca2+) influx into skeletal muscle cells, together with increased susceptibil-
ity to plasma membrane injury, is regarded as the initial trigger of muscle damage in DMD19–24. Targeting 
these early pathogenic events is considered essential for developing therapeutics for DMD.
In this study, we established a novel evaluation system to analyse the cellular basis of early DMD patho-
genesis by comparing DMD myotubes with the same clone but with truncated dystrophin-expressing 
DMD myotubes, using the exon-skipping technique. We demonstrated through in vitro contraction 
that excessive Ca2+ influx is one of the earliest events to occur in intact dystrophin-deficient muscle in 
response to electric stimuli. This event leads to extracellular leakage of CK in DMD myotubes. These 
results suggest that the early pathogenesis of DMD can be recapitulated with our system utilizing hiPSCs. 
Moreover, this system may enable the development of effective drugs that are applicable for most genetic 
variants of DMD by phenotypic screening based on early pathogenesis.
Results
Generation of tetracycline-inducible MyoD-transfected DMD patient-derived iPSCs (iPStet-
MyoD cells). Skin fibroblasts were biopsied from 2 different patients (age, 3 years 9 months and 
8 years 11 months) who were diagnosed with DMD and had deletion of exon 44 (Δ 44) and exon 
46–47 (Δ 46–47) in DMD, respectively, and from the 36-year-old biological father of the Δ 44-patient. 
Human iPS cells were generated from these fibroblasts by a previously established method using ret-
roviruses that carry the reprogramming factors Oct3/4, Sox2, Klf4, and L-Myc8,25. G4 and B7 were 
used as control cell lines26 and were both derived from the same person together with F4 and F6 from 
the father of Δ44 patient. MyoD, recognised as a master regulator gene for skeletal muscle differenti-
ation27, was constructed as the tetracycline-inducible MyoD piggyBac vector (Tet-MyoD) (Fig.  1a). 
Subsequent transfection to control and DMD hiPS cells was performed using an established method 
that allows well-controlled myogenic differentiation to occur at high efficiency26. Introduction of 
the Tet-MyoD to DMD and control hiPS cells, hereafter referred to as DMD- and Control-iPStet-MyoD, 
respectively, did not disrupt the pluripotent state8. These cells showed a flat and tightly packed cell mor-
phology (Supplementary Figure S1a) and maintained the ability to form a teratoma (Supplementary Figure 
S1b). To verify the undifferentiated state of the established DMD- and Control-iPStet-MyoD clones, the 
expression of the pluripotent stem cell markers Oct3/4, Sox2, and Nanog8 in these clones was confirmed by 
reverse transcriptase-PCR (RT-PCR) (Fig. 1b). Expression of stage-specific embryonic antigen (SSEA)-4 
and tumour-related antigen (TRA)-1–60, indicators for the undifferentiated stage of pluripotent stem 
cells, was detected by immunocytochemistry and alkaline phosphatase (AP) activity, further confirming 
that these hiPS cells retained stem cell characteristics after the introduction of the Tet-MyoD (Fig. 1c).
The skeletal muscle induction process consists of differentiation and maturation phases (Fig. 1d) and 
can be initiated by doxycycline (Dox) addition on day 1. The induction efficiency of MyoD was measured 
via flow cytometry using mCherry, and the efficiency of all clones was higher than 90%26 (Supplementary 
Figure S2a). Gene expression of oct 3/4, nanog, sox 2, exogenous- and endogenous-MyoD, and myogenin 
through differentiation was examined at days 0 (undifferentiated), 2, 4, 6, and 9. Upon activation of 
MyoD expression with Dox, pluripotent genes were significantly down-regulated (Fig. 1e), whereas genes 
for two endogenous myogenic regulatory factors, endogenous-MyoD and Myogenin, were up-regulated 
(Fig. 1f). Moreover, no endogenous or unrestrained expression of MyoD was detected from transfected 
Tet-MyoD at day 0 (Fig. 1f). The relative mRNA expression of endogenous-MyoD and Myogenin in each 
sample at day 9 of the induction demonstrated that differentiated skeletal muscle cells were comparable 
to skeletal muscle cells differentiated from the human myoblast cell line Hu5/E1828 (Fig. 1g).
Morphologically and physiologically comparable intact myotubes differentiated from control 
and DMD-derived hiPSCs. Transcripts of DMD, the skeletal muscle cell-specific gene creatine 
kinase-muscle (CKM), and tropomyosin 2 (TPM2)29, a Ca2+ channel marker recognised in matured contract-
ible muscle cells, were up-regulated at day 4 subsequent to over-expression of MyoD in Control-iPStet-MyoD 
and DMD-iPStet-MyoD cell-derived myocytes (denoted as Control- and DMD-Myocytes, respectively) 
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Figure 1. Generation and characterization of control and DMD patient-derived Tet-MyoD-transfected 
hiPS cells. (a) Construction of the tetracycline-inducible mCherry-linked MyoD piggyBac vector (Tet-MyoD). 
(b) RT-PCR analysis of Control-iPStet-MyoD (Father and B7) and DMD-iPStet-MyoD (Δ 44 and Δ 46–47) for 
pluripotency markers (Oct3/4, Sox2, and Nanog). (c) Immunocytochemistry for SSEA4 and TRA1–60 and 
alkaline phosphatase staining demonstrated the pluripotent state of Control-iPStet-MyoD Father and DMD-
iPStet-MyoD Δ 44. Scale bar, 200 μ m. (d) Skeletal muscle induction scheme for Tet-MyoD-transfected hiPS 
cells. Differentiation was initiated with Dox addition at day 1. Cells were cultured with 20% knockout serum 
replacement (KSR) hiPS medium for the first 2 days. (e) Quantitative RT-PCR analysis of Control-iPStet-MyoD 
and DMD-iPStet-MyoD showing relative expression of pluripotency markers Oct3/4, Nanog, and Sox2 and (f) 
myogenic markers exogenous- and endogenous-MyoD and Myogenin during the differentiation process. Data 
were normalised by setting day 0 = 1 for pluripotency markers, day 2 = 1 for exogenous-MyoD, and day 9 = 1 
for endogenous-MyoD and Myogenin. n = 3. Beta-actin was used as an internal control. (g) Relative expression 
of endogenous-MyoD and Myogenin at day 9 of differentiation in each sample. Gene expression levels were 
normalised by setting levels in the human myoblast cell line Hu5/E18 at day 5 of differentiation = 1. Ubiquitin 
C was used as an internal control. Black and white bars indicate Control- and DMD-Myocytes, respectively.
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(Fig.  2a). Relative mRNA expression at the end of the differentiation process at day 9 indicated that 
the differentiated skeletal muscle cells from DMD-iPStet-MyoD and Control-Myocytes were comparable 
(Fig. 2b). In all iPSC-derived skeletal muscle cells, the expression levels of mature muscle differentiation 
markers were comparable to those of the human myoblast cell line Hu5/E18. Immunocytochemistry 
demonstrated that both Control- and DMD-Myocytes differentiated similarly to form myotubes that 
express myosin heavy chain (MHC), CKM, and skeletal muscle actin (SMA) at day 9 of induction (Fig. 2c). 
Differentiation efficiency was calculated based on the number of MHC-positive cells compared to the 
total number of nuclei. The clones showed comparable differentiation efficiency (Supplementary Figure 
S2b). Whereas the amount of transcripts of DMD in both Control- and DMD-Myocytes increased from 
day 4 (Fig. 2a), the dystrophin protein was not detected in DMD-Myocytes (Fig. 2d). Electron micros-
copy did not reveal any significant morphological differences between Control- and DMD-Myocytes 
(Fig.  2e). We also examined the functional properties of both Control- and DMD-Myocytes by apply-
ing electric stimulation to promote contractions30. As a result, stimulated contractions were observed 
(Supplementary Movie S1) in differentiated myotubes together with twitch-synchronised Ca2+ uptake 
using the fluorescent dye Fluo-8 (data not shown). These results indicate that DMD-iPStet-MyoD clones 
efficiently differentiated to form multi-nucleated myotubes physiologically and morphologically compa-
rable to those of Control- Myocytes upon MyoD induction.
Exon-skipping with AO88 restored expression of Dystrophin in DMD myotubes differentiated 
from DMD-iPStet-MyoD cells. To examine the phenotypic changes caused by the loss of dystrophin, we 
applied antisense molecules to DMD-Myocytes to induce dystrophin protein expression by altering the 
splicing pattern to lead an in-frame shift achieved by an antisense oligonucleotide (AO) complementary 
to the target site31. We introduced AO88, an RNA/ENA AO that is a fully phosphorothioate-modified 
form of AO8532; it specifically skipped exon 45 to promote translation by linking exon 43 to exon 46 in 
the Δ 44-patient and exon 44 to exon 48 in the Δ 46–47-patient (Fig.  3b). The most appropriate time 
to deliver AO88 is when DMD expression is assured (Fig. 3a), which is around day 7 of differentiation 
(Fig. 2a). Because the electrophoresis demonstrated shorter PCR products without any incomplete skip-
ping remnants, exon-skipping denoted as+ AO was conducted efficiently (Fig. 3b). Western blotting anal-
ysis indicated that exon 45 skipping generated dystrophin protein that has the C-terminal end (Fig. 3c). 
Immunocytochemistry confirmed that the dystrophin protein was localised peripherally along the cell 
membrane in Control-Myocytes and also in AO-applied DMD-Myocytes (+ AO) (Fig.  3d). Similar to 
western blotting analysis, immunocytochemistry also demonstrated dystrophin protein expression in 
Control-Myocytes but not in DMD-Myocytes (Fig.  3d). From these results, we concluded that AO88 
efficiently induced exon 45 skipping in DMD-Myocytes from two different patients to express a trun-
cated dystrophin protein.
Restored dystrophin expression attenuates Ca2+ overflow in DMD-Myocytes. Myotubes were 
prepared on a 96-well plate and subjected to electric stimulation at 12 V, 0.2 Hz for 1 minute with Fluo-
8. The fluorescence intensity, which indicates Ca2+ influx in myotubes, appeared to be synchronised 
with electrical excitement as assessed by an FDSS/μ Cell plate-reader system. Representative amplification 
graphs of Fluo-8 intensity illustrate higher Ca2+ influx rates in DMD-Myocytes compared to the control, 
as indicated by the double arrowheads (Supplementary Figure S3a). There was a significant difference in 
Ca2+ influx level between DMD and Control-Myocytes when the average amplification values of 3 differ-
ent clones from each type of myotube were quantified (Supplementary Figure S3b). However, significant 
variance was seen in the Ca2+ influx for clones of the same myocyte type (Supplementary Figure S3c). 
Hence, for accurate measurements that eliminate the variability between clones, we compared Ca2+ influx 
within the same DMD-Myocytes clones by applying AO88. Ca2+ influx analysis was applied to 3 different 
types of DMD-Myocytes derived from the same patient: DMD-Myocytes (untreated), DMD-Myocytes 
treated with control oligonucleotide (DMD + CO), and DMD-Myocytes treated with AO88 (DMD + AO). 
Untreated DMD-Myocytes and DMD + CO exhibited significantly higher levels of Fluo-8 intensity than 
DMD + AO (Fig.  4a,b). Relative Fluo-8 intensities in the 2 different patients demonstrated a similar 
pattern, suggesting that the absence of dystrophin permits Ca2+ flow in excess compared to AO-treated 
DMD-Myocytes (Fig. 4b). To eliminate the possibility that these variances were resulted from differences 
in differentiation efficiency, we assessed the differentiation efficiency of each type of muscle cells. There 
were no significant morphological differences among untreated, DMD + CO, or DMD + AO treated skel-
etal muscle cells (Fig.  4c). Differentiation efficiency also did not show significant differences when all 
four clones were treated with CO or AO88 (Fig. 4d). Our synchronised electric stimulation system with 
Ca2+ visualisation and quantification supports previous reports indicating that excess Ca2+ flow occurs 
in DMD skeletal muscle cells23,33. Moreover, the truncated expression of dystrophin was sufficient to 
diminish increased Ca2+ flow in DMD myotubes. These findings suggest the necessity of the expression 
of the C-terminal end of the dystrophin protein to prevent excess Ca2+ flow in myocytes.
Ca2+ influx provokes skeletal muscle cellular damage in DMD muscle. To assess the effect of 
Ca2+ overflow on skeletal muscle cellular damage, cellular damage in the induced myocytes was eval-
uated by measuring the CK released in the supernatant (Fig. 5a). There were no significant differences 
in CK levels between Control- and DMD-Myocytes at baseline; the values ranged from 8 to 21 IU/L, 
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Figure 2. Morphologically and physiologically comparable skeletal muscle cells differentiated from 
Control-iPStet-MyoD and DMD-iPStet-MyoD. (a) Quantitative RT-PCR of skeletal muscle marker expression 
in skeletal muscle cells induced from Control-iPStet-MyoD and DMD-iPStet-MyoD, shown with black and white 
bars, respectively. Time course analyses were performed at days 0, 2, 4, 6, and 9. Relative mRNA levels of 
DMD, CKM, and TPM2 were analysed. Data were normalised by setting data from day 9 = 1. n = 3. Beta-
actin was used as an internal control. (b) Relative mRNA expression of DMD, CKM, and TPM2 at day 9 in 
Control- and DMD-Myocytes. Gene expression levels were normalised to those of Hu5/E18 cells at day 5 of 
differentiation. Ubiquitin C was used as an internal control. (c) Immunocytochemistry of MHC, CKM, and 
skeletal muscle actin (SMA) in skeletal muscle cells induced from Control-iPStet-MyoD and DMD-iPStet-MyoD  
merged with DAPI. All immunofluorescence analyses were conducted at day 9 of differentiation. Scale bar, 
200 μ m. (d) Western blotting analyses of dystrophin protein expression in induced myotubes detecting the 
rod domain and C-terminus. The intensity of each band was normalised to that of myosin heavy chain 
(MHC). Cells were collected at days 9–12 of differentiation. (e) Electron microscopy images of induced 
skeletal muscle cells from Control-iPStet-MyoD and DMD-iPStet-MyoD at day 9. Myofibrils and mitochondria are 
indicated with arrows and arrowheads, respectively. Scale bars, 1 μ m. 1:19,000 (Control) and 1:18,200 (DMD).
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with an average value of 14 IU/L (Fig. 5b). Previous reports have suggested that excessive influx of Ca2+ 
to myocytes indicates muscle cellular damage in muscular dystrophies22,23. Hence, to evaluate whether 
excess Ca2+ influx caused increased extracellular CK, ionomycin, an ionophore that induces Ca2+ influx 
in cells34, was added to measure CK activity. Addition of ionomycin indeed caused a dramatic change in 
CK activity: 2.9- to 4.5-fold in DMD-Myocytes and 2- to 3-fold in Control-Myocytes (Fig. 5c). Increased 
CK activity upon addition of ionomycin suggests that overflow of Ca2+ to the myotubes induces cel-
lular damage. It has been reported that transient receptor potential (TRP) family channels are poten-
tial candidate molecules underlying DMD pathology. To determine whether the excess Ca2+ influx that 
occurred in DMD-Myocytes was attributed to the TRP family channel, ruthenium red (RR), a TRP 
family inhibitor35, was added to block Ca2+ channels. Addition of RR significantly reduced CK activ-
ity in DMD-Myocytes, but not in Control-Myocytes (Fig.  5d). We also confirmed that there were no 
changes in CK activity alone with RR treatment (Supplementary Figure S4a). These analyses suggest 
that TRP family Ca2+ channels partially mediate the excessive Ca2+ influx that provokes skeletal mus-
cle cellular damage in DMD-Myocytes. To address the precise evaluation of exon-skipping efficiency, 
DMD-Myocytes were treated with two different concentrations of AO88 (100 nM and 200 nM), and the 
CK activity was measured. As shown by RT-PCR, the AO88 concentration affected the exon-skipping 
efficiency, as 100 nM AO88 treatment did not result in efficient exon 45 skipping, in contrast to 200 nM 
AO88 treatment (Fig. 5e). The effect of dystrophin protein expression on CK activity in DMD-Myocytes 
Figure 3. Restoration of dystrophin protein expression by AO88. (a) Transfection procedure for antisense 
oligonucleotide (AO) 88 in induced skeletal muscle cells. DMD-Myocytes were transfected with AO88 at 
day 7. Protein and RNA extraction was performed after 48 hours of transfection. (b) Exon 45 skipping was 
assessed by RT-PCR to compare Control-Myocytes (Father and B7) to DMD-Myocytes (Δ 44 and Δ 46–47). 
Exon 45 skipping led to an in-frame shift of exon 46 with Δ 44 and exon 48 with Δ 46–47, which resulted in 
smaller bands. (c) Western blotting analysis detecting the C-terminus of the dystrophin protein. AO-treated 
DMD-Myocytes showed restored expression of dystrophin protein. (d) Merged immunocytochemistry 
images for dystrophin and DAPI. Restored dystrophin protein expression was detected when samples were 
treated with AO88 (+AO). Scale bar, 20 μ m.
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was also examined. The different exon-skipping efficiency led to differences in CK activity, where 200 nM 
AO-treated samples showed significantly decreased CK activity compared to CO- and 100 nM AO-treated 
DMD-Myocytes (Fig. 5f). To visualise Ca2+ behaviour, Fluo-8 was introduced with ionomycin. Induced 
Ca2+ overflow was observed in the cytoplasm of myocytes upon ionomycin addition (Supplementary 
Figure S4b). DMD-myocytes exhibited significantly higher Fluo-8 intensity in response to ionomycin 
Figure 4. Restored expression of dystrophin diminishes Ca2+ influx in DMD muscle in response to 
electric stimulation. (a) Representative profiles of the Ca2+ influx pattern in Δ 44 and Δ 46–47 DMD-
Myocytes determined through Fluo-8 intensity in response to electric stimulation. AO88 (+ AO)- and 
control oligonucleotide (+ CO)-treated DMD-Myocytes were compared with untreated DMD-Myocytes. 
Electric pulses were applied to the cells 5 sec after the stationary phase at a constant frequency of 0.2 Hz at 
12 V for 1 min. The Ca2+ influx amplitude of AO-treated DMD-Myocytes was lower than that of untreated 
and + CO myocytes, as indicated by double arrowheads. (b) Quantitative analysis of Fluo-8 intensity 
amplification in Δ 44 and Δ 46–47 DMD-Myocytes. Amplification was normalised to that of untreated 
samples. n = 8, **p < 0.01. (c) Immunocytochemistry of MHC merged with DAPI in Δ 44 and Δ 46–467 
DMD-Myocytes, compared with that of AO- and CO-treated DMD-Myocytes. Scale bar, 200 μ m.  
(d) Quantitative analysis of the differentiation efficiency of two clones each from Δ 44 and Δ 46–47 DMD-
iPStet-MyoD. Percentages of MHC and DAPI double-positive fibres relative to total DAPI-positive cells at day 9 
of differentiation. n = 4.
www.nature.com/scientificreports/
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Figure 5. Ca2+ influx induces prominent skeletal muscle cellular damage in DMD-Myocytes.  
(a) Experimental design of the CK assay. (b) CK activity (IU/L) at the baseline condition of Control- and 
DMD-Myocytes, measured after 10 min of incubation at 37 °C. n = 6 with three independent experiments 
conducted for each assay. (c) Relative fold change in the CK value in Control- and DMD-Myocytes 
upon ionomycin addition, normalised against CK values for DMSO (control) addition. Two-way analysis 
of variance (ANOVA) revealed a significant difference in the rate of change between Control- and 
DMD- Myocytes in response to ionomycin treatment based on Scheffe’s test. **P < 0.01. n = 3 with three 
independent experiments conducted for each assay. (d) Relative fold change in the CK value with ionomycin 
and RR (a TRP family channel inhibitor) normalised to CK values with ionomycin treatment. Two-way 
ANOVA demonstrated a significant difference between control and DMD groups based on Scheffe’s test. 
**P < 0.01. (e) Exon 45 skipping with 2 different AO88 concentrations (100 nM and 200 nM) was assessed by 
RT-PCR and the results were compared to those for untreated and CO-treated DMD-Myocytes. Compared 
to 100 nM, 200 nM AO88 led to efficient exon 45 skipping, as demonstrated by a smaller band. (f) Relative 
fold change upon ionomycin addition in CO-treated and AO-treated DMD-Myocytes at 2 different 
concentrations was normalised to CK values in the case of DMSO (control) addition. n = 6, *P < 0.05, 
**P < 0.01.
www.nature.com/scientificreports/
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addition than Control- or DMD + AO myocytes (Supplementary Figure S4c). Thus, the expression of 
truncated proteins prevented the cellular damage caused by Ca2+ overflow.
Discussion
Experimental models of progressive diseases in vitro are indispensable for investigating primary pheno-
types and pathogeneses, especially at the onset, and for the development of therapies and treatments. In 
this study, we have recapitulated the early pathogenesis of DMD by creating an in vitro DMD model with 
myotubes generated from patient-derived iPS cells.
Skeletal muscle differentiation in myoblasts from DMD patients is generally delayed compared to 
that in healthy individuals11,36,37. In addition, extracted myoblasts or myofibres from DMD patients are 
more likely to be exposed to inflammatory signalling molecules. Our differentiation system successfully 
induced the formation of myotubes from DMD patients, and the myotubes displayed analogous mor-
phology and maturity compared with control myotubes, without any delay (Fig. 2a–c). One of the advan-
tages of using hiPSCs is that they provide an intact and homogeneous skeletal muscle cell population 
with almost simultaneous myogenic differentiation in both Control- and DMD-iPStet-MyoD populations. 
Furthermore, our method eliminates the variability in genetic background and enables evaluation of phe-
notypic variation using an identical DMD clone. Comparing myotubes generated from patient-derived 
iPS cells with those derived from the same DMD clones but expressing dystrophin by application of the 
exon-skipping technique enabled us to demonstrate the primary cellular phenotypes in skeletal muscle 
solely resulting from the loss of the dystrophin protein (Fig.  4b). The exon-skipping technique, which 
alters the splicing pattern to an in-frame shift, has been employed in many DMD studies to convert the 
phenotype of cells to that of Becker muscular dystrophy (BMD)1,6,38. Although both DMD and BMD 
result from deletions or mutations in the same DMD gene, BMD patients have later onset and present 
milder symptoms39. Our results demonstrate that truncated but functional dystrophin protein expression 
improved the cellular phenotype of DMD myotubes. These findings suggest that the expression of func-
tional dystrophin plays a critical role, particularly at the early stage of pathogenesis.
In DMD, the lack of dystrophin induces an excess influx of Ca2+ , leading to pathological dystrophic 
changes22. We consistently observed excess Ca2+ influx in DMD-Myocytes compared to Control-Myocytes 
(Supplementary Figure S3a and S3b) in response to electric stimulation. TRP channels, which are 
mechanical stimuli-activated Ca2+ channels40 that are expressed in skeletal muscle cells41, can account 
for this pathogenic Ca2+ influx. Previous reports have shown that suppression of TRP channels is accom-
panied by decreased Ca2+ influx in dystrophic fibres21. Moreover, it has been reported that Ca2+ influx 
induces muscular dystrophy in control myotubes through a TRP channel-dependent mechanism20 and 
that dominant-negative inhibition of Ca2+ influx via TRP channels ameliorates muscular dystrophy in 
animal models19. Thus, muscle fibres lacking dystrophin are more susceptible to unregulated Ca2+ influx, 
which leads to the activation of muscle degenerative pathways in DMD.
We have shown using identical clones that restoration of dystrophin protein expression via exon skip-
ping in DMD-myotubes suppresses Ca2+ overflow compared to untreated DMD-Myocytes in response 
to electric pulses (Fig. 4a), resulting in the alleviation of cellular damage (Fig. 5c). Moreover, addition of 
RR to DMD-Myocytes suppressed the leakage of CK significantly (Fig. 5d). These results indicate that the 
TRP channel family contributes to the DMD pathology. Thus, our study reinforces previous findings and 
shows that excessive Ca2+ influx into intact myotubes under contraction is indeed one of the primary and 
cell-autonomous phenotypes of DMD. These results are the first to demonstrate the importance of the 
dystrophin protein in cellular damage prevention using identical DMD-Myocytes. Furthermore, these 
findings suggest that hiPSc-derived myocytes provide in-depth modelling of the primary DMD cellular 
pathology. Because we established a real-time Ca2+ imaging and CK activity assay system with uniformly 
differentiated myotubes in a 96-well plate, our systematic evaluation system may provide a practical and 
efficient method for future drug screening42. The present study also revealed that this experimental sys-
tem can predict the effectiveness of exon skipping with customized antisense oligonucleotides in individ-
ual DMD patients by evaluating not only biochemical effects through western blotting (Fig. 3c) but also 
functional effects by measuring decreased Ca2+ influx into myotubes (Fig.  4a,b). Thus, our evaluation 
system is suitable for assessing the efficacy of exon-skipping drugs by phenotypic assay.
In conclusion, our study revealed that the absence of dystrophin protein induces skeletal muscle dam-
age by allowing excess Ca2+ influx in DMD myotubes. Our experimental system recapitulated the early 
phase of DMD pathology as demonstrated by visualisation and quantification of Ca2+ influx using intact 
myotubes differentiated from hiPS cells. Thus, our iPS cell-based in vitro model of DMD is a valuable 
and powerful tool for investigating the mechanisms and pathogenesis of DMD. This evaluation system 
significantly expands prospective applications with regard to assessing the effectiveness of exon-skipping 
drugs in individual DMD patients and also enabling the discovery of general drugs that regulate the 
initial events in DMD such as Ca2+ influx by phenotypic screening.
Methods
Ethical approval. Approval for the study was received from the Ethics Committee of the Graduate 
School of Medicine, Kyoto University and the Kyoto University Hospital (approval number #824 and 
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#G259) and conducted according to the guidelines of the Declaration of Helsinki. To protect confidenti-
ality, all information about the patients is kept anonymous and written informed consent was obtained.
Cell line and cell culture. Human dermal fibroblasts were donated from a 3-year, 9-month-old 
male and an 8-year, 11-month-old male, who have deletions in exon 44 and exon 46–47 of the DMD, 
respectively. Human dermal fibroblasts from the 36-year old biological father of Δ 44-patient were also 
obtained as a control. All human iPS cells used in this study were established by retroviral overexpression 
of 4 transcription factors, Oct3/4, Sox2, Klf4, and L-Myc, as previously described8,25.
Four control hiPSCs, the father of Δ 44-patient F4 and F6, G4 No. 35, and B7 No. 926, and 2 DMD 
patient-derived iPS cells, Δ 44 and Δ 46–47, were cultured and maintained on inactivated mouse feeder 
cells, as previously described8, in primate ES cell medium (ReproCELL, Japan) supplemented with 4 ng/
mL recombinant human basic fibroblast growth factor (bFGF, Wako).
MyoD Transfection. The MyoD element was cloned into the PB-TAC-ERN vector using Gateway 
cloning to yield PB-hMyoD as previously described26.
hiPSCs were treated with 10 μ M  Y-27632 (Nacalai Tesque) at least 2 hours prior to the transfec-
tion experiment. Treated hiPSCs were dissociated into single cells with accutase (Sigma), and 1.0 × 106 
cells were resuspeneded in Opti-MEM (GIBCO). Plasmid DNA (5 μ g of each), including PBase and 
PB-hMyoD, was transfected with an NEPA21 electroporator (Nepagene) using the conditions described 
in Table 1. Transfected cells were plated on mouse feeder cells at 2.0 × 105 and 8.0 × 105 cells/10 cm dish 
for clone selection and culture maintenance, respectively.
Skeletal muscle induction. hiPS-MyoD cells were trypsinised into single cells and plated on Matrigel 
(BD Biosciences) or on a collagen I (Iwaki)-coated dish with 5.0 × 105 to 1.0 × 106 cells per well on 
6-well plate dish in 20% KSR replacement media with 100 μ g/mL neomycin sulphate (Nacalai Tesque) 
and 10 μ M Y-27632 (Nacalai Tesque). The following day, culture medium was replaced with 1 μ g/mL 
doxycycline (Dox; LKT Laboratories) in 20% KSR replacement media. Induction was carried out in 5% 
KSR/α MEM media with Dox and 2ME supplement for 5 days. At day 7 of induction, the medium was 
switched to 2% horse serum/DMEM media until day 14.
Immunofluorescence analysis. Cultured cells were fixed with 100% methanol and subsequently 
blocked with Blocking One solution (Nacalai Tesque) at 4 °C. Fixed samples were layered in primary 
antibody, diluted in 10% Blocking One/0.01% Tween-20 (Santa Cruz)/PBS solution (PBST), and incu-
bated at 4 °C for overnight. Following serial washes with PBST, cells were incubated with secondary 
antibody diluted in 10% Blocking One/PBST solution for 1 hour. DAPI, a nuclear stain (Sigma), was 
loaded at 1:5000 dilution for 5 min. Samples were observed and images were taken with a BZ9000 system 
(Keyence) and LSM 710 confocal microscope (Carl Zeiss) at 200 × and 400 × magnification, respectively. 
Fluo-8 (AAT Bioquest) intensities were assessed by the BZ9000 system. Antibodies used in this study are 
listed in Supplementary Table S1.
Teratoma formation analysis. hiPSCs were suspended in Matrigel (BD, Biosciences) and inoculated 
into the tibialis anterior muscles of NOD/scid mice (Charles River Laboratories), which were previously 
treated with cardiotoxin under diethylether anaesthesia. Mice were dissected at 8–10 weeks after the cell 
transplantation.
Tumour sections were surgically removed and fixed in 4% paraformaldehyde (PFA)/PBS followed 
by substitution with 30% sucrose/PBS. Then, tumour samples were embedded in OCT compound 
(Tissue-Tek) and snap frozen on a carbon dioxide block. Frozen sections (10-μ m thick) were prepared 
for haematoxylin and eosin (HE) staining and immunohistochemistry.
Detecting Ca2+ influx via electric stimulation. Cells were differentiated on Matrigel-coated 96-well 
plates (Greiner). At day 9 of induction, cultured cells were loaded with Fluo-8, a fluorescent Ca2+ indi-
cator (AAT Bioquest) and incubated at 37 °C for 30 min. The detection of Ca2+ through electric stimu-
lation and the analyses were performed with an imaging plate reader FDSS/μ CELL system (Hamamatsu 
photonics). Electric stimulation was applied with electrical field stimulation (EFS) of 96 multi-electrodes 
at 12 V with a 50 ms interval and a 0.2 Hz mono phase for 1 min after 5 s of resting phase. The sampling 















Poring Pulse 125.0 5.0 50.0 2.0 10.0 + 
Transfer Pulse 20.0 50.0 50.0 5.0 40.0 + /−
Table 1. Parameters for electroporation of Tet-MyoD piggyBac vector transfection in hiPSCs.
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Emission was set at 540 nm using an emission filter and detected with an electron multiplying CCD 
(EMCCD) camera. Measurements for 96 wells were performed under uniform conditions at 37 °C with 
simultaneous stimulation and detection.
RNA extraction and quantitative real-time RT-PCR. Total RNA was extracted with Sepazol 
(Nacalai Tesque) following the manufacturer’s instructions. Extracted RNA was treated with DNase 
I (Invitrogen) to remove genomic DNA. cDNA synthesis was carried out with the Superscript III 
First-Strand Synthesis system for RT-PCR (Invitrogen) using either random hexamers or oligo dT as the 
primer. Quantitative real time RT-PCR was carried out with SYBR Green probe sets (Applied Biosystems) 
and a One Step thermal cycler (Applied Biosystems) and was performed in triplicate for each sample. 
Beta-actin and ubiquitin C were used as internal control for time course and day 9 differentiation analy-
sis, respectively. Primer sets used in this study are listed in Supplementary Table S2.
Protein extraction and Western blotting. Cells were lysed in 1% protease inhibitor cocktail (Roche) 
containing radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% 
Nonidet P-40 (NP-40), 1% sodium deoxycholate, and 0.1% SDS), by thorough sonication. Protein lysate 
(20–40 μ g) was mixed with an equal volume of EzApply (ATTO) and boiled at 95 °C for 5 min. Samples 
were then separated on a 3–8% NuPAGE Novex tris-acetate mini gel (Invitrogen) at 150 V for 75 min 
with the addition of NuPAGE antioxidant (Invitrogen) during electrophoresis. The fractionated proteins 
were transferred to a nitrocellulose membrane using an iBlot system (Invitrogen) with the program, 
P0, 13 min. The membrane was blocked with Membrane Blocking Agent (GE Healthcare life sciences) 
and incubated with primary antibody at 4 °C overnight. After 3 washes with PBST, the membrane was 
incubated with secondary antibody for 1 hour at room temperature. Refer Supplementary Table S1 for 
detailed antibody information.
Detection was carried out with Pierce ECL western blotting substrate (Thermo scientific). Visualisation 
and semi-quantification of images were performed by a ChemiDox XRS + imaging system (BIO-RAD).
Electron microscopy. Sample fixation and observation were carried out according to the Tokai 
Electron Microscopy, Inc. protocol that came with the instrumentation.
Antisense oligonucleotide (AO) transfection. AO88 and control oligonucleotide (CO), which is a 
fully phosphorothioated RNA/ENA antisense oligonucleotide for a non-myogenic gene, were introduced 
at day 7 to induced skeletal muscle cells at the final concentration of 200 nM or 100 nM for 3 hours with 
Lipofectamine 2000 (Life Technologies) by the method previously described43. Cells were cultured in 2% 
horse serum/ DMEM medium for 48 hours and collected for protein and RNA extraction.
CK value analysis. Cells were differentiated on Matrigel-coated 6-well plates. At day 9 of the induc-
tion, cells were washed with phenol red-free high glucose DMEM (Nacalai Tesque) and were replaced 
with the same media at 1 mL/well. Supernatant was collected from each well after 10 min of incubation 
at 37 °C and centrifuged at 1500 rpm for 5 min to eliminate any cell debris. Collected supernatants were 
supplemented with protease inhibitor cocktail (Nacalai Tesque) at 1:100 dilution and CK activity was 
measured by Oriental Yeast Co., LTD.
Ca2+ influx analysis was performed by adding 6.25 μ M ionomycin (Wako) or ionomycin and 1 μ M 
ruthenium red (Sigma) to cultured cells. Cells were then incubated for 10 min at 37 °C. Ca2+ uptake was 
visualised with Fluo-8 and measured with the BZ9000 system.
Flow cytometry analysis of mCherry positive Cells. Doxycycline-treated cells were washed in 
Phosphate buffered saline (PBS) and incubated for 5 min with accutase to dissociate into single cells. 
After cells were counted, they were suspended in Hank’s balanced salt solution (Life technologies), sup-
plemented with 1% BSA at 1.0 × 106 cells/100 μ L and analysed by an LSR Fortessa (BD Biosciences) for 
the expression of mCherry.
Statistical analysis. All experiments were performed in triplicate and repeated at least twice. The 
data representing in all figures are means and standard deviation of the mean. Ca2+ uptake assays using 
electric stimulation were carried out with n = 12 for the Control- and DMD-Myocytes comparison 
and n = 8 for the DMD and DMD-Myocytes + AO comparison. The data in Figs  4b,d, 5e, S3b, S3c 
and S4c are presented using the two-tailed Student’s t test for independent samples by R software. The 
data in Fig. 5b–d, S2b and S4a are presented using the Scheffe’s test to compare Control-Myocytes with 
DMD-Myocytes samples by R software. Values of P < 0.05 were considered significant.
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